Combining targeted radionuclide therapy and immunotherapy could improve melanoma survival

(Society of Nuclear Medicine and Molecular Imaging) Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows that combining targeted radionuclide therapy with immunotherapy could improve the survival of patients with metastatic melanoma.

Comments